Professor Jorge Cortes (Georgia Cancer Center, Augusta, GA, USA) shares the long-term efficacy and safety data from the 96-week update of the ASCEMBL trial of asciminib with a novel mechanism of action in patients with Philadelphia chromosome-positive chronic myeloid leukaemia chronic phase.
The abstract ‘Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update’ (Abstract 7004) was presented at the the 2022 American Society of Clinical Oncology (ASCO) annual meeting.
Disclosures: Jorge Cortes is consultant for, and has received grant/research support from Novartis, Pfizer, Takeda and Sun Pharma. He is also on the Advisory Board for Novartis and Pfizer.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.
